Exelixis, Inc. (EXEL)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Exelixis, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Exelixis, Inc. (EXEL) has returned -2.14% so far this year and 16.17% over the past 12 months. Looking at the last ten years, EXEL has achieved an annualized return of 26.62%, outperforming the S&P 500 Index benchmark, which averaged 12.16% per year.

Based on dividend-adjusted daily data since Apr 17, 2000, EXEL's average daily return is +0.10%, while the average monthly return is +1.90%. At this rate, your investment would double in approximately 3.1 years.

Historically, 53% of months were positive and 47% were negative. The best month was Nov 2002 with a return of +83.4%, while the worst month was Sep 2014 at -63.0%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 8 months.

On a daily basis, EXEL closed higher 49% of trading days. The best single day was Jul 20, 2015 with a return of +50.4%, while the worst single day was Sep 2, 2014 at -55.3%.

Exelixis, Inc. has an annualized alpha of 15.76%, beta of 1.31, and R² of 0.16 versus S&P 500 Index. Calculated based on daily prices since April 18, 2000.

• This stock captured 179.82% of S&P 500 Index gains and 157.75% of its losses — amplifying both gains and losses, but participating more in upside than downside.
• R² of 0.16 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

EXEL ranks 54 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Exelixis, Inc. (EXEL) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Exelixis, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Exelixis, Inc. was 97.38%, occurring on Dec 24, 2014. The portfolio has not yet recovered.

The current Exelixis, Inc. drawdown is 12.91%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Exelixis, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Exelixis, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.